Kröll Dino, Borbély Yves Michael, Dislich Bastian, Haltmeier Tobias, Malinka Thomas, Biebl Matthias, Langer Rupert, Candinas Daniel, Seiler Christian
Department of Surgery, Campus Charité Mitte and Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Department of Visceral Surgery and Medicine, Inselspital Bern, Bern University Hospital and University of Bern, 3010, Bern, Switzerland.
BMC Surg. 2020 Sep 11;20(1):197. doi: 10.1186/s12893-020-00855-z.
Although considered complex and challenging, esophagectomy remains the best potentially curable treatment option for resectable esophageal and esophagogastric junction (AEG) carcinomas. The optimal surgical approach and technique as well as the extent of lymphadenectomy, particularly regarding quality of life and short- and long-term outcomes, are still a matter of debate. To lower perioperative morbidity, we combined the advantages of a one-cavity approach with extended lymph node dissection (usually achieved by only a two-cavity approach) and developed a modified single-cavity transhiatal approach for esophagectomy.
The aim of this study was to evaluate the outcome of an extended transhiatal esophageal resection with radical bilateral mediastinal en bloc lymphadenectomy (eTHE). A prospective database of 166 patients with resectable cancers of the esophagus (including adenocarcinomas of the AEG types I and II) were analyzed. Patients were treated between 2001 and 2017 with eTHE at a tertiary care university center. Relevant patient characteristics and outcome parameters were collected and analyzed. The primary endpoint was 5-year overall survival. Secondary outcomes included short-term morbidity, mortality, radicalness of en bloc resection and oncologic efficacy.
The overall survival rates at 1, 3 and 5 years were 84, 70, and 61.0%, respectively. The in-hospital mortality rate after eTHE was 1.2%. Complications with a Clavien-Dindo score of III/IV occurred in 31 cases (18.6%). A total of 25 patients (15.1%) had a major pulmonary complication. The median hospital stay was 17 days (interquartile range (IQR) 12). Most patients (n = 144; 86.7%) received neoadjuvant treatment. The median number of lymph nodes resected was 25 (IQR 17). The R0 resection rate was 97%.
In patients with esophageal cancer, eTHE without thoracotomy resulted in excellent long-term survival, an above average number of resected lymph nodes and an acceptable postoperative morbidity and mortality.
尽管食管癌切除术被认为复杂且具有挑战性,但对于可切除的食管癌和食管胃交界部(AEG)癌来说,它仍然是最有可能实现治愈的最佳治疗选择。最佳手术方式和技术以及淋巴结清扫范围,尤其是在生活质量和短期及长期疗效方面,仍是一个有争议的问题。为降低围手术期发病率,我们将单腔手术方式的优势与扩大淋巴结清扫(通常仅通过双腔手术方式实现)相结合,开发了一种改良的单腔经裂孔食管切除术。
本研究的目的是评估扩大经裂孔食管切除术联合根治性双侧纵隔整块淋巴结清扫术(eTHE)的疗效。分析了一个前瞻性数据库,该数据库包含166例可切除食管癌患者(包括I型和II型AEG腺癌)。患者于2001年至2017年在一所三级医疗大学中心接受eTHE治疗。收集并分析了相关患者特征和疗效参数。主要终点是5年总生存率。次要结局包括短期发病率、死亡率、整块切除的根治性和肿瘤学疗效。
1年、3年和5年的总生存率分别为84%、70%和61.0%。eTHE术后的院内死亡率为1.2%。Clavien-Dindo评分III/IV级的并发症发生在31例患者中(18.6%)。共有25例患者(15.1%)发生严重肺部并发症。中位住院时间为17天(四分位间距(IQR)12天)。大多数患者(n = 144;86.7%)接受了新辅助治疗。切除淋巴结的中位数为25个(IQR 17个)。R0切除率为97%。
对于食管癌患者,不进行开胸的eTHE导致了优异的长期生存率、高于平均水平的切除淋巴结数量以及可接受的术后发病率和死亡率。